

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



山東新華製藥股份有限公司

**Shandong Xinhua Pharmaceutical Company Limited**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 00719)**

### RESUMPTION OF TRADING

Reference is made to the announcements of the Shandong Xinhua Pharmaceutical Company Limited (the “**Company**”) dated 27 April 2022 in relation to the trading halt of its shares and subsequently the release of inside information of the Company concerning the entering into of a strategic cooperation agreement.

The board of directors of the Company (the “**Board**”) announces that the trading in the shares of the Company on The Stock Exchange of Hong Kong Limited will be resumed at 9:00 a.m. 28 April 2022 (Thursday).

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board

**Shandong Xinhua Pharmaceutical Company Limited**

Zhang Daiming

*Chairman*

28 April 2022, Zibo, the PRC

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Zhang Daiming (Chairman)

Mr. Du Deping

Mr. He Tongqing

Independent Non-executive Directors:

Mr. Pan Guangcheng

Mr. Zhu Jianwei

Mr. Lo Wah Wai

Non-executive Directors:

Mr. Cong Kechun

Mr. Xu Lie